Publications

Search
Found 41 results
Filters: Author is Law, M.R.  [Clear All Filters]
2010
Law M, Lu CY, Soumerai SB, Graves AJ, LeCates RF, Zhang F, et al. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clinical therapeuticsClin.Ther.. 2010;32(4):729-41; discussion 716.
Law M, Grépin KA. Is newer always better? Re-evaluating the benefits of newer pharmaceuticals. Journal of health economicsJ.Health Econ.. 2010;29(5):743-750.
Law M, Grépin KA. Is newer always better? Re-evaluating the benefits of newer pharmaceuticals. Journal of health economics. 2010;29(5):743-750.
McGrail KM, Law M, Hébert PC. No more dithering on e-health: let’s keep patients safe instead. Canadian Medical Association Journal. 2010;182(6):535.
2009
Law M, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Archives of Internal MedicineArch.Intern.Med.. 2009;169(21):1969-1974.
Law M, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Archives of internal medicine. 2009;169(21):1969.
2008
Law M, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ (Clinical research ed.)BMJ. 2008;337:a1055.
Law M, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ: British Medical Journal. 2008;337.
Law M, Ross-Degnan D, Soumerai S. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric Services. 2008;59(5):540-546.
Law M, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric services (Washington, D.C.)Psychiatr.Serv.. 2008;59(5):540-546.
Law M, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. The Journal of clinical psychiatry. 2008;69(1):47.
Law M, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. The Journal of clinical psychiatryJ.Clin.Psychiatry. 2008;69(1):47-53.
Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law M, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs. 2008;27(3):w185-w195.
Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law M, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health affairs (Project Hope)Health.Aff.(Millwood). 2008;27(3):w185-95.
2004
Law M, Brown P, Windsor J. Variation in specialist fees: evidence from New Zealand insurance claims. Journal of Health Services Research & Policy. 2004;9(suppl 2):48-55.

Pages